T. Rowe Price Associates’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$124M Buy
3,212,815
+648,753
+25% +$24M 0.01% 574
2025
Q4
$91.1M Buy
2,564,062
+2,474,346
+2,758% +$69.6M 0.01% 647
2025
Q3
$1.29M Buy
89,716
+16,564
+23% +$196K ﹤0.01% 1946
2025
Q2
$526K Buy
73,152
+18,766
+35% +$104K ﹤0.01% 2275
2025
Q1
$326K Buy
54,386
+4,743
+10% +$37.2K ﹤0.01% 2427
2024
Q4
$388K Buy
49,643
+5,486
+12% +$54.7K ﹤0.01% 2392
2024
Q3
$477K Buy
44,157
+3,540
+9% +$34.5K ﹤0.01% 2265
2024
Q2
$343K Buy
40,617
+5,406
+15% +$41K ﹤0.01% 2358
2024
Q1
$237K Buy
35,211
+4,030
+13% +$24.9K ﹤0.01% 2538
2023
Q4
$184K Buy
31,181
+1,526
+5% +$11.7K ﹤0.01% 2570
2023
Q3
$290K Buy
29,655
+4,286
+17% +$50.8K ﹤0.01% 2346
2023
Q2
$301K Buy
25,369
+1,868
+8% +$21.4K ﹤0.01% 2365
2023
Q1
$254K Buy
23,501
+12,379
+111% +$158K ﹤0.01% 2426
2022
Q4
$129K Buy
11,122
+1,018
+10% +$12.6K ﹤0.01% 2660
2022
Q3
$151K Buy
+10,104
New +$138K ﹤0.01% 2627

Other funds holding COGT